Mainz Biomed N.V. (MYNZ) Institutional Ownership

Ownership Summary

A total of 13 institutions have reported a stake in Mainz Biomed N.V. (NASDAQ:MYNZ) as of September 2025, according to recent 13F filings with the SEC.

• Mainz Biomed N.V saw its institutional ownership percentage rose to 20.8% in September 2025 from 16.6% in June 2025.
• In percentage terms, this reflects as a holdings change of 28.87% quarter on quarter, and an increase of 18.18% year over year.
• Of these 13 institutional investors, 4 increased their holdings in Mainz Biomed N.V, while 3 of them reduced positions, and 6 investors maintained their exposure.
• This class of investors increased its holdings in Mainz Biomed N.V to 481.83K shares for the 13F-cycle ending September 2025, up by 107.93K shares quarter on quarter, and up 314.93K shares year over year.
• As of September 30, 2025, ARMISTICE CAPITAL, LLC held Mainz Biomed N.V's largest shareholding position with over 394.52K shares, representing 17.01% of total outstanding shares.
• Among the most significant buyers of Mainz Biomed N.V during September 2025 were ARMISTICE CAPITAL, LLC (109.52K), Dauntless Investment Group, LLC (1.00K), OSAIC HOLDINGS, INC. (1.00K), ROTHSCHILD INVESTMENT LLC (85).
• Leading sellers of Mainz Biomed N.V stock in September 2025 included UBS Group AG (2.81K), MORGAN STANLEY (860), SBI Securities Co., Ltd. (3).
• The top 10 institutional holders of Mainz Biomed N.V for the quarter ending September 2025 included ARMISTICE CAPITAL, LLC (394.52K), Dauntless Investment Group, LLC (51.00K), Journey Advisory Group, LLC (15.00K), Steward Partners Investment Advisory, LLC (10.00K), UBS Group AG (7.00K), OSAIC HOLDINGS, INC. (2.11K), Provenance Wealth Advisors, LLC (1.17K), Newbridge Financial Services Group, Inc. (500), SBI Securities Co., Ltd. (337), IFP Advisors, Inc (90).